rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Passage Bio, Inc.

PASG · Nasdaq

Health CareBiotechnologyNot moving yet

PASG stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 35.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 26
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$412K
Insider sales, 12 months
$226K
Officials’ trades on record
0
Institutions holding
27 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$231K$0$698KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months2
Buyers · sellers2 · 2
WhoDidSharesTraded
Lynx1 Capital Management Lp10% ownerbought50,055at $4.1225 Jun 2026filed 29 Jun 2026
William ChouPRESIDENT AND CEOsold4,076at $18.448 Jan 2026filed 12 Jan 2026
Kathleen BorthwickCFOsold2,062at $18.448 Jan 2026filed 12 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders27-4 on the quarter
New · exited5 · 9
Reported value$11.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 20262,886,125$4.3M+2,886,125
Lynx1 Capital Management LPadded · filed 12 Aug 2026673,759$3.3M+50,055+8.0%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026113,964$556K00.0%
Balyasny Asset Management L.P.new · filed 14 Aug 2026107,025$522K+107,025
Ikarian Capital, LLCadded · filed 14 Aug 202699,517$486K+31,393+46.1%
Yiheng Capital Management, L.P.unchanged · filed 14 Aug 202686,097$420K00.0%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202647,892$234K-85,720−64.2%
Erste Asset Management GmbHreduced · filed 28 Jul 202640,665$197K-44,597−52.3%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202637,026$181K-4,354−10.5%
Verdad Advisers, LPadded · filed 14 Aug 202630,728$150K+8,600+38.9%
31 Mar 2023 – 30 Jun 2026
283848Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Lynx1 Capital Management LP Company insider10% owner · last 25 Jun 20268 · 0
Weston Nichols Company insider10% owner · last 25 Jun 20264 · 0
Athena Countouriotis Company insiderDirector · last 19 May 20262 · 0
Derrell Porter Company insiderDirector · last 19 May 20260 · 0
Dolan Sondhi Company insiderDirector · last 19 May 20260 · 0
Maxine Gowen Company insiderDirector · last 19 May 20260 · 0
Sandip Kapadia Company insiderDirector · last 19 May 20261 · 1
Thomas Richard Kassberg Company insiderDirector · last 19 May 20260 · 0
Kathleen Borthwick Company insiderCFO · last 16 Mar 20260 · 4
William Chou Company insiderPRESIDENT AND CEO · last 16 Mar 20260 · 1
ORBIMED ADVISORS LLC Company insider10% owner · last 26 Jun 20253 · 13
Saqib Islam Company insiderDirector · last 28 May 20251 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-126%
Share count trendFY 2025 · to 26 Feb 20260.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$46.3M

Analyst forecasts

No analyst forecasts yet.